Atenolol Pathway


Atenolol competes with sympathomimetic neurotransmitters such as catecholamines for binding at beta(1)-adrenergic receptors in the heart and vascular smooth muscle, inhibiting sympathetic stimulation. This results in a reduction in resting heart rate, cardiac output, systolic and diastolic blood pressure, and reflex orthostatic hypotension. Higher doses of atenolol also competitively block beta(2)-adrenergic responses in the bronchial and vascular smooth muscles.

Pathway legend Zoom in

Pathway Image

Pathway legend Zoom in

References

  1. Borchard, U. (1998). Pharmacological properties of beta-adrenoceptor blocking drugs. Journal of Clinical and Basic Cardiology, 1(1), 5-9.
  2. DiPiro, J.T., Talbert, R.L., Yee, G.C., Matzke, G.R., Wells, B.G, & Posey, M.L. (2005). Pharmacotherapy: A pathologic approach. (6 th ed) pp.207-208. New York: McGraw-Hill Medical Publishing Division.
  3. Tenormin. (2009). [Electronic version]. e-CPS. Retrieved July 25, 2009.